BACKGROUND: IBD comprises Crohn’s disease (CD) and ulcerative colitis (UC), both are characterized by unpredictable exacerbations and remissions. The incidence is highest in adolescence and early adulthood, and unlike other chronic diseases, there can be a considerable impact upon patients’ HRQoL. Few studies assessing HRQoL have been performed in adolescents and young adults (AYA) with IBD. Our objectives were to estimate IBD-related quality of life (HROQL) in AYA patients with inflammatory bowel disease (IBD) and analyze the diseases factors that could influence it.

METHODS: 59 AYA IBD patients (13-25y) at two gastroenterology units of tertiary hospitals was evaluated and compared to 60 AYA healthy controls (13-25y). 59 AYA IBD patients completed the Pediatric Quality of Life Inventory 4.0 (PedsQL®). Short Form Health Survey (SF-36) questionnaires and Pain Visual Scale, according to age. After we compared HRQoLru between Crohn’s disease (CD) vs. UC (ulcerative colitis) in AYA population. The demographic data, extra-intestinal manifestations, overlap syndromes, disease active status, treatment and outcomes were also evaluated. All participants and the adolescents’ legal guardian written informed consent form.

RESULTS: PedsQL-4.0 domain ‘school’ work’ and SF-36 domain ‘general health perception’ was reduced in IBD AYA patients compared with healthy controls (P < 0.05). In addition, significantly lower score “health change” in SF-36 in comparison with healthy determined perceived differences in state of health over the past year. No difference in other domains and pain scale was observed between CD and UC AYA patients. Disease activity as well extra intestinal manifestations, overlap syndromes, treatments and outcomes did not influence the HROQL of the AYA patients. Autoimmune serologing cholangitis and the use of prednisone were significantly higher among UC patients, whereas previous gut surgery was higher between CD patients. However, these disease factors did not significantly influence the HROQL between CD vs UC. Mann-Whitney test and Fisher’s test were used to compare continuous variables and comparison between groups, P < 0.05 was considered statistically significant.

CONCLUSION: HROQL was significant lower for AYA with IBD relative to healthy controls. This result highlights areas to focus clinical attention in adolescents and young adult patients with IBD for assessment and future interventions.

P010
The Influence of COVID-19 on Inflammatory Bowel Disease-Related Search Trends
Canako And DBG1, Murphy Megan2, Terr Marci3, Jang Tinja4, Mattar Mark5
1Bouton University Medical Center/Boston Medical Center, Boston, United States; 2Medstar Georgetown University Hospital, Washington, United States.

BACKGROUND: The novel SARS-CoV-2 Coronavirus pandemic has had significant global impact on health care. The pandemic’s effect on patients with inflammatory bowel disease (IBD) is unknown, and health care delivery to this largely immunocompromised population is of concern. As many patients refrained or were unable to seek in-person medical care. We noticed there was a decrease in IBD related Emergency Department (ED) visits. Thus, we aimed to explore if the pandemic influenced IBD specific search trends in the United States.

METHODS: Using Google Trends (GT), we queried Crohn’s Disease (CD) or Ulcerative Colitis (UC) in combination with IBD-related symptoms (i.e. bloating, rectal bleeding, abdominal pain and diarrhea) or medications (i.e. infliximab and prednisone) between January 1 and April 30 for the years 2018 and 2020. Frequencies of the specific search terms were compared to the site’s relative search volume over weekly and monthly intervals. IBD related ED visits were also collected from July 2018 to July 2020. Data was analyzed using monthly and weekly mean search scores compared across years and through 2020 using ANOVA with post-hoc Tukey adjustment for multiple comparisons.

RESULTS: There were decreased search scores for bloating and rectal bleeding with IBD terms compared across years and through 2020 using ANOVA with post-hoc Tukey adjustment for multiple comparisons. Of patients with moderately-to-severely active CD. Given the importance of PA on IBD patient outcomes, PA interventions aimed to explore if the pandemic influenced IBD specific search trends in the United States. The Inflammation of COVID-19 on Inflammatory Bowel Disease-Related Search Trends

CONCLUSION: Infliximab-induced remission following maintenance therapy has been shown to be effective for increasing PA levels in day to day life as shown by increase in the number of steps taken per day as well as by reduced inactive time on patients with moderately-to-severely active CD. The impact of PA on IBD patient outcomes may be useful therefore, along with targeted PA recommendations for increasing PA levels. Furthermore, strategies of treatment associated with an exercise program must be considered for this population.

P012
Ozanimod Reduced Fecal Calprotectin Levels in Patients with Ulcerative Colitis in the Phase 3 True North Study
Ghulam Shafi1,2, D’Haens Geert3, Janarth Vidal4, Rieder Florian5, Peterson Anna-Katrin6, Usnik Rok7, Chakrava Denevik8, Canakis Andrew9, Lucca 10
1University of Calgary, Calgary, Canada; 2Inflammatory Bowel Disease Center, Amsterdam University Medical Center, Amsterdam, Netherlands; 3Western University, London, Canada; 4Cleveland Clinic, Cleveland, United States; 5Bristol-Meyers Squibb Company, Princeton, United States; 6Mount Sinai Medical Center, New York, United States.

BACKGROUND: Ozanimod is an orally-administered sphingosine-1-phosphate (SIP) receptor modulator that binds with high affinity to SIP1 and SIP3 receptor subtypes. Ozanimod demonstrated efficacy and safety for up to 52 weeks of treatment in patients with moderately-to-severely active ulcerative colitis (UC) in the double-blind, randomized, phase 3 True North study. Fecal calprotectin (FCP), which occurs as a consequence of neutrophils in the gastrointestinal tissue from an inflammatory process, is strongly correlated with endoscopic activity in UC. The aim of this analysis was to assess the change in FCP in a prespecified biomarker analysis of patients in the True North study.

METHODS: True North was a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of oral ozanimod HCl 1 mg/day (equal to ozanimod 0.92 mg) vs placebo once daily over a 10-week induction period and a 42-week maintenance period in patients with moderately-to-severely active UC. The induction period, patients were randomized to receive double-blind ozanimod or placebo and patients in Cohort 2 received open label ozanimod. Patients in either cohort who responded to ozanimod at week 10 were re-randomized to receive double-blind ozanimod or placebo for the maintenance period up to week 52. FCP was assessed at baseline, week 10, and week 52. The proportion of patients with FCP response stratified by baseline FCP was evaluated at weeks 10 and 52.

RESULTS: At baseline, mean FCP levels were 2595 µg/g in patients randomized to ozanimod (n = 422) and 3440 µg/g in those randomized to placebo (n = 214) in Cohort 1. A total of 451 patients who responded to ozanimod in the induction period (Cohort 1 and Cohort 2) were re-randomized in the maintenance period and had FCP data; 226 continued to receive ozanimod (mean baseline FCP, 2284 µg/g) and 225 received placebo (mean baseline FCP, 2987 µg/g). FCP levels were significantly improved with ozanimod vs placebo in both induction and maintenance periods. Mean (SD) change in FCP for ozanimod vs placebo was -470.2 (6887.9) µg/g vs 21.1 (7919.3) µg/g at week 10 (P = 0.002) and -157.1 (4427.9) µg/g vs -463.7 (3770.6) µg/g at week 52 (P = 0.019). Of patients with elevated FCP at baseline with cutoffs of >30 and >150 µg/g, significantly more patients had reduced FCP levels below those respective cutoffs at week 10 with ozanimod vs placebo: 21% vs 6% and 33% vs 13% respectively (P < 0.001). Of patients with low FCP at baseline who remained on ozanimod were significantly more likely to have FCP levels below these cutoffs vs those clinical responders re-randomized to placebo, 46% vs 24% and 57% vs 38% for baseline FCP >30 and >150 respectively (P < 0.01, both).

Ozanimod Reduced Fecal Calprotectin Levels in Patients with Ulcerative Colitis in the Phase 3 True North Study

CONCLUSION: In patients with moderately-to-severely active UC, ozanimod led to significant reductions in FCP during induction and maintenance therapy, with a greater proportion of patients achieving FCP response with ozanimod vs placebo across multiple baseline FCP cutoffs. These results are consistent with the inhibition of inflammation in the gut by ozanimod in patients with moderate-to-severe UC.